$EYPT

EyePoint, Inc. Stock 12‑Month Price Target Cut to $20.89, Implies 599% Upside

EyePoint, Inc.'s average stock price target was reduced from $22.33 to $20.89 by analysts, with a range of $1 to $48. This implies a 599% upside from the Oct. 16 closing price. The consensus rating remains 'Buy' among 13 analysts, with 5 Buys, 8 Holds, and 0 Sells.

Original reporting
Published Oct 19, 2026, 10:20 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 19, 2026, 10:29 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
EyePoint, Inc. Stock 12‑Month Price Target Cut to $20.89, Implies 599% Upside — source image
Decision brief

The 30-second read

$EYPTBearishLow
01

Why it matters

The price‑target reduction may trigger short‑term sell pressure, but the stock still shows high implied upside.

02

Market read

Analyst target cut is the primary new fact, offering modest trading relevance for the stock.

03

What to watch

Potential upcoming product launches or contract wins not yet reflected in analyst models.

Relevance 5/10Novelty 5/10Timing: today

Background

EyePoint is a micro‑cap technology company with recent analyst coverage.

Company-level read

Ticker impact

$EYPTBearishMedium confidence
Context

Analysts cut EyePoint's average 12‑month price target to $20.89 from $22.33, implying reduced upside.

Expected impact

potential downward pressure as investors reassess valuation

Evidence & confidence

Price‑target cuts often precede short‑term price declines, especially for low‑float microcaps.

Market effects

Minimal impact on broader sector; reflects analyst view on EyePoint only.

None

None

Counterpoint

Target cut may be overly cautious; upside could remain if upcoming catalysts materialize.

Key entities

  • EyePoint, Inc.

    Subject of the price‑target revision.

Related articles

$AZNHigh

Why AZN, VSXY, EYPT Stocks Are Moving Premarket Today

AstraZeneca (AZN) shares rose 1.8% premarket after Oracle (ORCL) announced a non-binding AI collaboration. Victoria’s Secret (VSXY) gained 1% following a Barclays price target increase to $112. EyePoint Pharmaceuticals (EYPT) fell 4.4% after JPMorgan downgraded it to 'Underweight' due to a clinical trial setback.

$EYPTMedAI 8/10

JPMorgan downgrades EyePoint stock rating on trial failures

JPMorgan downgraded EyePoint Inc. (EYPT) to Underweight after its LUCIA trial failed to meet the primary endpoint. The company will focus on diabetic macular edema trials, with data expected in 2027. Multiple analysts downgraded EYPT, citing trial setbacks and cash burn concerns. The stock has fallen 85.67% in a week, with a market cap of $37.93 million.

$EYPTHighAI 8/10

Jefferies downgrades Eyepoint stock rating on trial miss

Jefferies downgraded EyePoint Inc. (NASDAQ:EYPT) to Hold, cutting its price target to $1.00 from $8.00. The stock fell 86% to $0.45 after its Phase 3 LUCIA study missed its primary endpoint. The company has $118 million in cash but faces cash burn and extended timelines for other programs. Multiple analysts have downgraded the stock due to trial setbacks.